Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7951 to 8000 of 8900 results

  1. Laparoscopic surgery for colorectal cancer (TA17)

    This guidance has been replaced by NICE technology appraisal guidance 105. 

    Withdrawn guidance

  2. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

    Withdrawn guidance

  3. Rituximab for the treatment of rheumatoid arthritis (TA126)

    This guidance has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  4. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Withdrawn guidance

  5. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Withdrawn guidance

  6. Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)

    This guideline has been updated and replaced by NICE guideline NG185.

    Withdrawn guidance

  7. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy (TA232)

    The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.

    Withdrawn guidance

  8. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance

  9. Abatacept for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA234)

    This guidance has been updated and replaced by NICE technology appraisal guidance 280.

    Withdrawn guidance

  10. Roflumilast for the management of severe chronic obstructive pulmonary disease (TA244)

    This guidance has been updated and replaced by NICE technology appraisal guidance 461.

    Withdrawn guidance

  11. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)

    This guidance has been updated and replaced by NICE technology appraisal guidance 425.

    Withdrawn guidance

  12. Pharmalgen for the treatment of bee and wasp venom allergy (TA246)

    This guidance has been withdrawn because Pharmalgen products no longer have a marketing authorisation in the UK.

    Withdrawn guidance

  13. Guidance on the use of gemcitabine for the treatment of pancreatic cancer (TA25)

    This guidance has been replaced by NICE guideline NG85.

    Withdrawn guidance

  14. Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (TA248)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  15. Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)

    This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.

    Withdrawn guidance

  16. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251)

    This guidance has been updated and replaced by NICE technology appraisal guidance 426.

    Withdrawn guidance

  17. Ranibizumab for the treatment of diabetic macular oedema (TA237)

    This guidance has been updated and replaced by NICE technology appraisal guidance 274.

    Withdrawn guidance

  18. Wound care - debriding agents (TA24)

    This guidance has been replaced by NICE guideline CG74.

    Withdrawn guidance

  19. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252)

    Telaprevir no longer has a marketing authorisation in the UK so this guidance has been withdrawn.

    Withdrawn guidance

  20. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253)

    Boceprevir is no longer available in the UK so this guidance has been withdrawn.

    Withdrawn guidance

  21. Cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA255)

    This guidance has been updated and replaced by NICE technology appraisal guidance 391.

    Withdrawn guidance

  22. Docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer (TA26)

    This guidance has been replaced by NICE guideline CG24 [Replaced by NICE guideline CG121].

    Withdrawn guidance

  23. Adalimumab for the treatment of moderate to severe ulcerative colitis (terminated appraisal) (TA262)

    This guidance has been updated and replaced by NICE technology appraisal guidance 329.

    Withdrawn guidance

  24. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  25. Liraglutide for the treatment of type 2 diabetes mellitus (TA203)

    This guidance has been updated and replaced by NICE guideline NG28.

    Withdrawn guidance

  26. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)

    This guidance has been updated and replaced by NICE technology appraisal guidance 293.

    Withdrawn guidance

  27. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

    Withdrawn guidance

  28. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)

    This guidance has been replaced by NICE technology appraisal guidance 326.

    Withdrawn guidance

  29. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

    Withdrawn guidance

  30. Guidance on the Selection of Prostheses for Primary Total Hip Replacement (TA2)

    This guidance has been updated and replaced by NICE technology appraisal guidance 304.

    Withdrawn guidance

  31. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)

    This guidance has been updated and replaced by NICE technology appraisal guidance 278.

    Withdrawn guidance

  32. Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

    This guidance has been updated and replaced by NICE technology appraisal guidance 432.

    Withdrawn guidance

  33. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Withdrawn guidance

  34. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Withdrawn guidance

  35. Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) (TA224)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  36. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy (TA41)

    This guidance has been updated and replaced by NICE technology appraisal guidance 156. 

    Withdrawn guidance

  37. Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

    This guidance has been updated and replaced by NICE technology appraisal guidance 736.

    Withdrawn guidance

  38. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

    This guidance has been updated and replaced by NICE technology appraisal guidance 795.

    Withdrawn guidance

  39. Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

    This guidance has been updated and replaced by NICE technology appraisal guidance 739.

    Withdrawn guidance

  40. Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

    This guidance has been updated and replaced by NICE technology appraisal guidance 616.

    Withdrawn guidance

  41. Liquid-based cytology for cervical screening (TA5)

    This guidance has been replaced by NICE technology appraisal guidance 69.

    Withdrawn guidance

  42. Imanitib for chronic myeloid leukaemia (TA50)

    This guidance has been updated and replaced by NICE technology appraisal guidance 70 [Partially updated by NICE technology appraisal guidance 241].

    Withdrawn guidance

  43. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

    Withdrawn guidance

  44. Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

    We have withdrawn the guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.

    Withdrawn guidance

  45. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

    Withdrawn guidance

  46. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

    This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.

    Withdrawn guidance

  47. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    This guidance has been updated and replaced by NICE technology appraisal guidance 752.

    Withdrawn guidance

  48. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Withdrawn guidance

  49. Ischaemic heart disease - coronary artery stents (TA4)

    This guidance has been replaced by NICE technology appraisal guidance 71. 

    Withdrawn guidance

  50. The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease (TA40)

    This guidance has been updated and replaced by NICE technology appraisal guidance 187.

    Withdrawn guidance